Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31466611 | 0.91 | PIM1 (0.52) | PIM1PDK2FFAR1FFAR4HDAC1 | |
| SCHEMBL2095220 | 0.91 | PIM1 (0.52) | PIM1PDK2FFAR1FFAR4HDAC1 | |
| SCHEMBL8370558 | 0.90 | PIM1 (0.48) | PIM1PDK2FFAR1FFAR4HDAC1 | |
| SCHEMBL8955822 | 0.88 | PDK2 (0.49) | PIM1PDK2FFAR1FFAR4HDAC1 | |
| SCHEMBL16363945 | 0.86 | ALDH1A1 (0.48) | ALDH1A1RECQLPDK2HDAC1HDAC2 | |
| SCHEMBL2091806 | 0.85 | CETP (0.44) | PIM1FFAR1CETP | |
| SCHEMBL48418 | 0.84 | ALDH1A1 (0.70) | ALDH1A1RECQLSYK | |
| Ethylene Glycol SCHEMBL7206927 | 0.82 | ALDH1A1 (0.67) | ALDH1A1RECQLSYK | |
| SCHEMBL7008638 | 0.82 | TAAR1 (0.52) | PDK2CHRM5 | |
| SCHEMBL3720181 | 0.82 | CETP (0.42) | HDAC1HDAC2CETPCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| CN-107082782-B | Substituted xanthines and methods of use thereof | 海德拉生物科学有限责任公司 | 2020-03-20 | — | — | CN | disclosed |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-10399982-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-7071180-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2006-07-04 | — | — | US | disclosed |
| EP-1178973-B1 | PYRAZINYL-PIPERAZINE- COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2005-12-21 | — | — | EP | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | ALDH1A1 763/4885RECQL 2320/4885PIM1 4864/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | ALDH1A1 724/4885RECQL 2293/4885PIM1 4868/4885 |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | ALDH1A1 1647/4885RECQL 1124/4885PIM1 4822/4885 |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | ALDH1A1 1647/4885RECQL 1124/4885PIM1 4822/4885 |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | ALDH1A1 716/4885RECQL 3532/4885PIM1 3323/4885 |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | ALDH1A1 1647/4885RECQL 1124/4885PIM1 4822/4885 |
| US-10399982-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | ALDH1A1 1647/4885RECQL 1124/4885PIM1 4822/4885 |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | ALDH1A1 1647/4885RECQL 1124/4885PIM1 4822/4885 |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | ALDH1A1 1647/4885RECQL 1124/4885PIM1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.